Sufentanil Intranasal

Launched by CENTRE HOSPITALIER UNIVERSITAIRE SAINT PIERRE · Oct 22, 2019

Keywords

ClinConnect Summary

This clinical trial is studying a medication called sufentanil, which is given through the nose, to see how well it helps relieve severe pain in patients who have recently experienced trauma, like an injury from an accident. The researchers are looking for people who are experiencing significant pain (rated 7 out of 10 or higher) that has lasted less than 24 hours and who come to the emergency department.

To participate, individuals must be between the ages of 18 and 74 and should not have certain conditions such as being pregnant, having severe allergies to pain medications, or being unstable due to other health issues. Participants will receive the sufentanil treatment and will be monitored to assess how effective it is in managing their pain. It's important for potential participants to understand that their safety is a priority, and they will be screened carefully to ensure they meet the eligibility criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • posttraumatic pain + lasting for less than 24 hours + with an analog visual pain scale of 7/10 or more
• Exclusion Criteria:
• • pregnant
• • \<18 years
• • prisoners
• • lesions of head, face or abdomen
• • no consent given or possible
• • pain not scorable
• • known drug abuse or substitution therapy
• • chronic level 3 pain medication
• • intake of level 3 \< 8 hours
• • intoxicated patient
• • allergy or intolerance to opiates
• • renal or hepatic insufficiency
• • \< 50kg body weight
• • hemodynamic instability